Successful treatment of refractory schizophrenia with combined olanzapine and quetiapine in a patient with a prolactin secreting pituitary microadenoma

Journal of Psychopharmacology

Volumn 19, Issue 1, 2005, Pages 97-101

  Dunkley, Melanie J ^a   Reveley, Michael A ^a,b  

^a LEICESTER GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Olanzapine; Pituitary microadenoma; Prolactin; Quetiapine; Treatment resistant schizophrenia

Indexed keywords

CHLORPROMAZINE; FLUOXETINE; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; QUETIAPINE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; BREAST AUGMENTATION; BREAST TENDERNESS; CASE REPORT; COMBINATION CHEMOTHERAPY; EXPERIENCE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GALACTORRHEA; GYNECOMASTIA; HIRSUTISM; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; IMPOTENCE; LIBIDO DISORDER; MENSTRUATION DISORDER; PATHOLOGICAL ANATOMY; PRESCRIPTION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SIDE EFFECT; THERAPY RESISTANCE; TREATMENT FAILURE; TREATMENT PLANNING; WEIGHT GAIN;

ADENOMA; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIBENZOTHIAZEPINES; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; PITUITARY NEOPLASMS; PROLACTIN; SCHIZOPHRENIA;

EID: 12444307401     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269881105048903     Document Type: Article

References (25)

1. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn (DSM-IV). American Psychiatric Association, Washington, DC
2. British Medical Association and the Royal Pharmaceutical Society of Great Britain (2003) British National Formulary 46: 000
3. Colonna L, Saleem P, Dondey-Nouvel L, Rein W (2000) Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Int Clin Psychopharmacol 15: 13-22
4. Grunder G, Wetzel H, Schlosser R, Anghelescu I, Hillert A, Lange K, Hiemke C, Benkert O (1999) Neuroendocrine response to antipsychotics: effects of drug type and gender. Biol Psychiatry 45: 89-97
5. Henderson D C, Goff D C (1996) Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 57: 395-397
6. Kane J M (1992) Clinical efficacy of clozapine in treatment-refractory schizophrenia - an overview. Br J Psychiatry 160 (Suppl 17): 41-45
7. Kleinberg D L, Davis J M, De Coster R, Van Baelen B, Brecher M (1999) Prolactin levels and adverse effects in patients treated with risperidone. J Clin Psychopharmacol 19: 57-61
8. Korbonits M, Grossman A B (2000) Drug-induced hyperprolactinaemia. Prescribers' J 40: 157-164
9. Lerner V, Chudakova B, Kravets S, Polyakova I (2000) Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case report series. Clin Neuropharmacol 23: 284-286
10. Malhotra S, Butler B, Oxenkrug G (2001) Switch from risperidone to olanzapine: normalization of prolactinemia and receding of pituitary adenoma. Biol Psychiatry 49: 56S
11. 2 receptor occupancy and clinical response in amisulpride augmentation of clozapine non-response. J Psychopharmacol 15 (Suppl): A41
12. Meltzer H Y, Fang V S (1976) The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry 33: 279-286
13. Meltzer H, Bastani B, Jayathilake K, Maes M (1997) Fluoxetine, but not tricyclic antidepressants, potentiates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder. Neuropsychopharmacology 17: 1-11
14. Moncrieff J (2003) Clozapine versus conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination. Br J Psychiatry 183: 161-166
15. Peterson M C (2001) Reversible galactorrhoea and prolactin elevation related to fluoxetine use. Mayo Clin Proc. 76: 215-216
16. Raskin S, Durst R, Katz G, Zislin J (2000a) Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia. J Clin Psychopharmacol 20: 500-503
17. Raskin S, Katz G, Zislin Z, Knobler H Y, Durst R (2000b) Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation. Acta Psychiatr Scand 101: 334-336
18. Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P, Modai I, Khaikin M, Weizman A (1997) Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. Br J Psychiatry 171: 569-573
19. 123I]-epidepride single photon emission tomography (SPET) study. Br J Psychiatry 177: 408-415
20. Takhar J (1999) Pimozide augmentation in a patient with drug-resistant psychosis previously treated with olanzapine. J Psychiatry Neurosci 24: 248-249
21. Thompson C (1994) The use of high-dose antipsychotic medication. Br J Psychiatry 164: 448-458
22. Turrone P, Kapur S, Seeman M V, Flint A J (2002) Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 159: 133-135
23. Wahlbeck K, Cheine M, Essali M A (2000) Clozapine versus typical neuroleptic medication for schizophrenia (Cochrane Review). The Cochrane Library, Issue 4. John Wiley, Chichester
24. Windgassen K, Wesselmann U, Schulze Monking H (1996) Galactorrhoea and hyperprolactinaemia in schizophrenic patients on neuroleptics: frequency and aetiology. Neuropsychobiology 33: 142-146
25. World Health Organization (1993) ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. World Health Organization, Geneva